[go: up one dir, main page]

MA40534B1 - Inhibiteurs de mk2 et leurs utilisations - Google Patents

Inhibiteurs de mk2 et leurs utilisations

Info

Publication number
MA40534B1
MA40534B1 MA40534A MA40534A MA40534B1 MA 40534 B1 MA40534 B1 MA 40534B1 MA 40534 A MA40534 A MA 40534A MA 40534 A MA40534 A MA 40534A MA 40534 B1 MA40534 B1 MA 40534B1
Authority
MA
Morocco
Prior art keywords
inhibitors
compositions
compounds
methods
relates
Prior art date
Application number
MA40534A
Other languages
English (en)
Other versions
MA40534A (fr
Inventor
Deqiang Niu
Joseph John Mcdonald
Russell C Petter
Juswinder Singh
Matthew David Alexander
Claudio Chuaqui
John Malona
Yike Ni
Chittari Pabba
Original Assignee
Celgene Car Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Car Llc filed Critical Celgene Car Llc
Publication of MA40534A publication Critical patent/MA40534A/fr
Publication of MA40534B1 publication Critical patent/MA40534B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La présente invention concerne des composés, leurs compositions et des méthodes pour les utiliser.
MA40534A 2014-09-17 2015-09-16 Inhibiteurs de mk2 et leurs utilisations MA40534B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051788P 2014-09-17 2014-09-17
US201562199927P 2015-07-31 2015-07-31
PCT/US2015/050495 WO2016044463A2 (fr) 2014-09-17 2015-09-16 Inhibiteurs de mk2 et leurs utilisations

Publications (2)

Publication Number Publication Date
MA40534A MA40534A (fr) 2016-03-24
MA40534B1 true MA40534B1 (fr) 2021-04-30

Family

ID=55454109

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40534A MA40534B1 (fr) 2014-09-17 2015-09-16 Inhibiteurs de mk2 et leurs utilisations

Country Status (30)

Country Link
US (5) US9458175B2 (fr)
EP (2) EP3912981A1 (fr)
JP (3) JP6556225B2 (fr)
KR (1) KR102457848B1 (fr)
CN (1) CN106998692B (fr)
AU (1) AU2015317741B2 (fr)
BR (1) BR112017005266B1 (fr)
CA (1) CA2961607C (fr)
CL (1) CL2017000576A1 (fr)
CO (1) CO2017003279A2 (fr)
CY (1) CY1124215T1 (fr)
DK (1) DK3193611T3 (fr)
EA (1) EA037299B1 (fr)
EC (1) ECSP17023281A (fr)
ES (1) ES2874561T3 (fr)
HR (1) HRP20210529T1 (fr)
HU (1) HUE054347T2 (fr)
IL (1) IL251051B (fr)
LT (1) LT3193611T (fr)
MA (1) MA40534B1 (fr)
MX (2) MX373341B (fr)
PL (1) PL3193611T3 (fr)
PT (1) PT3193611T (fr)
RS (1) RS62017B1 (fr)
SA (1) SA517381115B1 (fr)
SG (2) SG11201701861RA (fr)
SI (1) SI3193611T1 (fr)
SM (1) SMT202100311T1 (fr)
TW (1) TWI744217B (fr)
WO (1) WO2016044463A2 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014238443A1 (en) 2013-03-15 2015-07-30 Celgene Car Llc MK2 inhibitors and uses thereof
SI3193611T1 (sl) 2014-09-17 2021-08-31 Celgene Car Llc Inhibitorji MK2 in njihove uporabe
CN106632077B (zh) * 2016-10-10 2019-01-22 上海再启生物技术有限公司 一种2-氨基-4-溴嘧啶的制备方法
JP2020514360A (ja) * 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の形態および組成物
WO2018170203A1 (fr) * 2017-03-16 2018-09-20 Celgene Car Llc Inhibiteurs de mk2, leur synthèse et leurs intermédiaires
US11098057B2 (en) 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
WO2018170201A1 (fr) * 2017-03-16 2018-09-20 Celgene Car Llc Analogues deutérés d'inhibiteurs de mk2 et leurs utilisations
JP7200120B2 (ja) * 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
CN107058259A (zh) * 2017-05-18 2017-08-18 南京中医药大学 分子标志物mk2基因及其应用
JP7692353B2 (ja) * 2018-10-02 2025-06-13 ディスク・メディスン，インコーポレイテッド マトリプターゼ２阻害剤及びその使用
US20220251105A1 (en) * 2019-05-17 2022-08-11 Celgene Car Llc Methods of treating a mk2-mediated disorder
CN115484956A (zh) * 2020-02-14 2022-12-16 萨克生物研究学院 使用ulk1/2抑制剂的单一疗法和联合疗法
EP4114411A4 (fr) * 2020-03-02 2024-04-24 Washington University Compositions et méthodes pour le traitement du cancer du pancréas
JP2023536427A (ja) * 2020-07-24 2023-08-25 ブリストル－マイヤーズ スクイブ カンパニー 急性呼吸器障害の治療方法
EP4244341A4 (fr) * 2020-11-12 2025-01-15 Akttyva Therapeutics, Inc. Composés d'activation de mk2 destinés à être utilisés dans le traitement de fuites vasculaires et de troubles de la barrière endothéliale
CN116670142A (zh) * 2021-02-01 2023-08-29 细胞基因公司 Mk2抑制剂、其合成和其中间体
EP4079855A1 (fr) * 2021-04-20 2022-10-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Composé et procédé pour la prophylaxie et le traitement de la leucémie
CN117940433A (zh) * 2021-08-27 2024-04-26 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
CA3242679A1 (fr) 2022-01-14 2023-07-20 Shanghai Hansoh Biomedical Co., Ltd. Derive polycyclique contenant de la pyridine, son procede de preparation et son utilisation
WO2024044731A1 (fr) * 2022-08-26 2024-02-29 Matchpoint Therapeutics Inc. Composés diazépino-thiéno-quinoxaline et leur utilisation en thérapie
CN120390642A (zh) * 2022-10-27 2025-07-29 百时美施贵宝公司 Mk2抑制剂及其用途
CN120676947A (zh) * 2023-02-07 2025-09-19 细胞基因公司 可用作mk2激酶降解剂的化合物和组合物
WO2024229401A2 (fr) * 2023-05-04 2024-11-07 Matchpoint Therapeutics Inc. Composés de diazépino-thiéno-quinoxaline et leur utilisation en thérapie
WO2025002076A1 (fr) * 2023-06-26 2025-01-02 深圳信立泰药业股份有限公司 Utilisations d'un inhibiteur de mk2 dans la préparation de médicaments pour la prévention et/ou le traitement de maladies

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015778A (en) 1989-12-18 1991-05-14 The Dow Chemical Company Catalytic method to produce hydroxy substituted arylophenones
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
US6861440B2 (en) * 2001-10-26 2005-03-01 Hoffmann-La Roche Inc. DPP IV inhibitors
TW200413273A (en) 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
EP1572693A1 (fr) 2002-12-20 2005-09-14 Pharmacia Corporation Composes inhibant la proteine kinase-2 activee par la proteine kinase activee par des agents mitogenes
JP5010917B2 (ja) 2003-08-29 2012-08-29 エグゼリクシス， インコーポレイテッド ｃ−Ｋｉｔ調節因子および使用方法
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
AU2006210513C1 (en) 2005-02-04 2012-10-25 Senomyx, Inc. Compounds comprising linked heteroaryl moieties and their use as novel umami flavor modifiers, tastants and taste enhancers for comestible compositions
EP1849781A1 (fr) 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Dérivés de 3-Amino-4-hydroxy pyrrolidine, procédé de fabrication et utilisation come medicaments
EP2223925A1 (fr) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase
AR067535A1 (es) 2007-07-16 2009-10-14 Novartis Ag Derivados de lactama tetraciclicos
CN101910151A (zh) 2007-10-22 2010-12-08 先灵公司 双环杂环衍生物及其作为gpr119活性调节剂的用途
BRPI0914682B8 (pt) 2008-06-27 2021-05-25 Avila Therapeutics Inc compostos de heteroarila e composições compreendendo os referidos compostos
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010048149A2 (fr) 2008-10-20 2010-04-29 Kalypsys, Inc. Modulateurs hétérocycliques de gpr119 pour le traitement d'une maladie
US20110269744A1 (en) * 2010-03-12 2011-11-03 Astellas Pharma Inc. Benzazepine Compound
WO2011153553A2 (fr) * 2010-06-04 2011-12-08 The Regents Of The University Of California Méthodes et compositions pour l'inhibition de kinases
EP2508511A1 (fr) * 2011-04-07 2012-10-10 Laboratoire Biodim Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
ES2742261T3 (es) * 2011-04-15 2020-02-13 Hivih Inhibidores de la replicación viral, su proceso de preparación y sus usos terapéuticos
WO2013124040A1 (fr) 2012-02-22 2013-08-29 Merck Patent Gmbh Milieu cristallin liquide
WO2013146963A1 (fr) * 2012-03-28 2013-10-03 武田薬品工業株式会社 Composé hétérocyclique
TW201406758A (zh) * 2012-06-28 2014-02-16 Daiichi Sankyo Co Ltd 三環性化合物
US9085586B2 (en) * 2012-07-11 2015-07-21 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
EP2898421A4 (fr) * 2012-09-24 2016-07-13 Claremont Speede Accès à des données contrôlé par un expéditeur mobile, et procédé et système de suppression de données
TW201417817A (zh) * 2012-09-25 2014-05-16 Daiichi Sankyo Co Ltd Ｇｓｋ３抑制劑與抗ｄｒ５抗體之組合
AU2014238443A1 (en) * 2013-03-15 2015-07-30 Celgene Car Llc MK2 inhibitors and uses thereof
WO2014139144A1 (fr) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Composés et compositions thérapeutiques
WO2015050957A2 (fr) 2013-10-02 2015-04-09 Treatments For Systemic Lupus Erythematosus Traitements du lupus érythémateux systémique
WO2016032882A1 (fr) 2014-08-25 2016-03-03 Stc.Unm Inhibition de mk2 dans le traitement du cancer
SI3193611T1 (sl) 2014-09-17 2021-08-31 Celgene Car Llc Inhibitorji MK2 in njihove uporabe
JP2018502860A (ja) 2015-01-08 2018-02-01 モイライ マトリックス インコーポレイテッド Ｍｋ２阻害ペプチド製剤
US11098057B2 (en) 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
WO2018170203A1 (fr) 2017-03-16 2018-09-20 Celgene Car Llc Inhibiteurs de mk2, leur synthèse et leurs intermédiaires
JP2020514360A (ja) 2017-03-16 2020-05-21 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤の形態および組成物
WO2018170201A1 (fr) 2017-03-16 2018-09-20 Celgene Car Llc Analogues deutérés d'inhibiteurs de mk2 et leurs utilisations
JP7200120B2 (ja) 2017-03-16 2023-01-06 セルジーン シーエーアール エルエルシー Ｍｋ２阻害剤として有用なヘテロアリール化合物
US20220251105A1 (en) 2019-05-17 2022-08-11 Celgene Car Llc Methods of treating a mk2-mediated disorder
JP2023536427A (ja) 2020-07-24 2023-08-25 ブリストル－マイヤーズ スクイブ カンパニー 急性呼吸器障害の治療方法

Also Published As

Publication number Publication date
BR112017005266A2 (pt) 2017-12-12
US20210053984A1 (en) 2021-02-25
WO2016044463A3 (fr) 2016-09-01
CY1124215T1 (el) 2022-05-27
US10253040B1 (en) 2019-04-09
EP3193611B1 (fr) 2021-03-24
SG10201902326XA (en) 2019-04-29
SA517381115B1 (ar) 2021-03-09
US10577380B2 (en) 2020-03-03
WO2016044463A2 (fr) 2016-03-24
JP2017529367A (ja) 2017-10-05
MX2017003359A (es) 2017-11-22
EA037299B1 (ru) 2021-03-05
CA2961607A1 (fr) 2016-03-24
RS62017B1 (sr) 2021-07-30
LT3193611T (lt) 2021-08-25
BR112017005266B1 (pt) 2022-11-01
AU2015317741B2 (en) 2020-01-16
SMT202100311T1 (it) 2021-07-12
US20170114073A1 (en) 2017-04-27
CN106998692B (zh) 2020-09-08
CN106998692A (zh) 2017-08-01
US9790235B2 (en) 2017-10-17
CA2961607C (fr) 2023-03-28
US20160075720A1 (en) 2016-03-17
CO2017003279A2 (es) 2017-09-29
EP3193611A2 (fr) 2017-07-26
MA40534A (fr) 2016-03-24
SG11201701861RA (en) 2017-04-27
US11584757B2 (en) 2023-02-21
EA201790380A1 (ru) 2017-08-31
ES2874561T3 (es) 2021-11-05
HRP20210529T1 (hr) 2021-08-06
US20190375762A1 (en) 2019-12-12
AU2015317741A1 (en) 2017-04-20
MX2020005213A (es) 2020-08-20
JP7375072B2 (ja) 2023-11-07
MX373341B (es) 2020-05-26
TWI744217B (zh) 2021-11-01
PT3193611T (pt) 2021-05-28
IL251051B (en) 2019-11-28
EP3193611A4 (fr) 2018-02-28
SI3193611T1 (sl) 2021-08-31
ECSP17023281A (es) 2017-06-30
JP2022078315A (ja) 2022-05-24
PL3193611T3 (pl) 2021-10-04
TW201617351A (zh) 2016-05-16
NZ730603A (en) 2024-02-23
KR20170063734A (ko) 2017-06-08
IL251051A0 (en) 2017-04-30
JP6556225B2 (ja) 2019-08-07
US9458175B2 (en) 2016-10-04
CL2017000576A1 (es) 2017-12-01
KR102457848B1 (ko) 2022-10-25
DK3193611T3 (da) 2021-05-10
EP3912981A1 (fr) 2021-11-24
JP2019194236A (ja) 2019-11-07
HUE054347T2 (hu) 2021-08-30

Similar Documents

Publication Publication Date Title
MA40534A (fr) Inhibiteurs de mk2 et leurs utilisations
EA201891251A1 (ru) Бициклические ингибиторы pad4
MX2022005177A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
PH12018500457A1 (en) New phenoxymethyl derivatives
MX2018006148A (es) Inhibidores de cxcr2.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2015008999A (es) Inhibidores mk2 y usos de los mismos.
EA201891910A1 (ru) Гетероарильные ингибиторы pad4
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201790173A1 (ru) Антитела, связывающие axl
EA201992177A1 (ru) Композиции на основе нирапариба
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
MX2016003843A (es) Inhibidores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos.
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
MX2018004674A (es) Moduladores de interacción de sestrina-gator2 y sus usos.
EA201891347A1 (ru) Аза-бензимидазольные ингибиторы pad4
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
EA201790184A1 (ru) Пестицидные композиции
MA41803A (fr) Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques
EA201600026A1 (ru) Бактериальная гиалуронидаза и способ ее производства
TW201613934A (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
MX384131B (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y métodos.
EA201691549A1 (ru) Ариллактамные ингибиторы киназы
MA39824A (fr) Composés azole amido-substitués